# Abbisko Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abbisko-therapeutics-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.abbisko.com
- Total disclosed funding: $263M
- Latest round: Series D (Jan 7, 2021)
- Investors on record: 19

## About

Abbisko Therapeutics Co., Ltd., based in Shanghai, China, specializes in developing and commercializing innovative oncology therapeutics aimed at addressing significant unmet medical needs.Founded in 2016, Abbisko Therapeutics Co., Ltd. focuses on producing targeted small molecule drugs for cancer treatment. The company's headquarters is located in Shanghai, China. Dr. Yao-Chang Xu serves as CEO, leading a team with extensive expertise in drug development. In January 2021, Abbisko raised USD 123.00 mn in Series D funding, which was co-led by Carlyle Group and Warburg Pincus, among others. The firm has successfully completed 4 deals to date.Abbisko is primarily engaged in the development and commercialization of innovative therapeutics, focusing on addressing unmet medical needs in oncology. The company's flagship products include a range of small molecule drugs designed to target specific cancer pathways, thereby enhancing treatment efficacy and minimizing side effects. These products are engineered for use in both monotherapy and combination therapy settings, catering to a diverse patient population across various stages of cancer treatment. The therapeutic solutions aim to improve outcomes for patients suffering from advanced solid tumors and hematologic malignancies, with a commitment to advancing personalized medicine. Abbisko's core offerings are marketed primarily in the Asia-Pacific region, with significant engagement in markets such as China and Japan, reflecting the company’s strategic focus on regions with high patient demand for novel cancer therapies.Abbisko generates revenue through a combination of partnerships, direct sales, and collaborations with healthcare providers and research institutions. The company engages in B2B transactions, primarily working with hospitals and specialty clinics that administer its therapeutic products. Revenue streams are augmented through strategic alliances with pharmaceutical companies, which may involve co-development and licensing agreements for its proprietary drug candidates. Additionally, Abbisko's pricing structure is designed to reflect the value provided by its innovative solutions, with contracts often negotiated on a case-by-case basis depending on the treatment regimens and patient accessibility. The firm is committed to maintaining transparency and fostering long-term relationships with its clients, ensuring that its products effectively reach the healthcare market while addressing the evolving needs of oncology patients.Following the recent Series D funding in January 2021, Abbisko Therapeutics Co., Ltd. plans to utilize the USD 123.00 mn raised to accelerate its clinical programs and expand its preclinical pipeline, which consists of multiple programs in discovery to IND-enabling stages. The company aims to launch new oncology products and expand its market presence, particularly focusing on the Asia-Pacific region, where there is a growing demand for innovative cancer therapies. Specific release dates for new products have not been disclosed, but the company's strategy includes significant engagement in markets such as China and Japan.

## Funding rounds

- Series D, Jan 7, 2021, $123M — Carlyle Group, OrbiMed Advisors, Warburg Pincus, Temasek Holdings, Qiming Venture Partners, Lilly Asia Ventures, Sage Partners, China International Capital Corporation, Janchor Partners, Lake Bleu Capital, Shanghai Healthcare Capital, Greater Bay Area Homeland Investments Limited, Hankang Capital
- Series C, Mar 25, 2020, $70M — GIC, Qiming Venture Partners, Lilly Asia Ventures, Temasek Holdings, China International Capital Corporation, Loyal Valley Capital, CCB Principal Capital Management
- Series B, Mar 22, 2019, $42M — Qiming Venture Partners, Lilly Asia Ventures, China International Capital Corporation, Loyal Valley Capital, TF Capital
- Series A, Feb 9, 2017, $28M — Lilly Asia Ventures, Shanghai Jianyi Private Equity Fund Management, TF Capital, CCB Private Equity Investment Management

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B, Series C, Series D
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A
- TF Capital — Series A, Series B
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series C, Series D
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B, Series C, Series D
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B, Series C
- GIC — Series C
- Temasek Holdings — Series C, Series D
- CCB Principal Capital Management — Series C
- Carlyle Group (https://capitalatlas.ai/funds/carlyle-group) — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series D
- Sage Partners (https://capitalatlas.ai/funds/sage-partners) — Series D
- Janchor Partners — Series D
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series D
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series D
- Greater Bay Area Homeland Investments Limited (https://capitalatlas.ai/funds/greater-bay-area-homeland-investments-limited) — Series D
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series D